Abiomed pushes ahead with AbioCor trial
This article was originally published in Clinica
Abiomed is pressing on with a clinical trial for its AbioCor heart replacement. The Danvers, Massachusetts firm has implanted the device in the tenth of 15 patients authorised by the FDA for the study. Three patients are currently still being supported with the device. "We believe we have recaptured the momentum lost in 2002, and are working diligently to maintain that momentum," said Dr Robert Kung, the firm's chief scientific officer.